Agios Pharmaceutical (AGIO) 45.22 $AGIO Agios to Webcast

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Agios Pharmaceutical (AGIO) 45.22 $AGIO

Agios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016
GlobeNewswire - Thu Jul 28, 3:01PM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, August 4, 2016 at 8:30 a.m. ET to report its second quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 45.22 (-0.01)

Dr. Michael Rosenblatt Joins Flagship Ventures as Chief Medical Officer
PR Newswire - Tue Jul 12, 11:00PM CDT
Flagship Ventures today announced the appointment of industry veteran Michael Rosenblatt, M.D., to the new position of Chief Medical Officer. In this capacity, Dr. Rosenblatt will lead global clinical development and medical affairs for the organization. He will play a key role in Flagship's internal venture creation team during the conception and launch of the next generation of pioneering biotechnology companies as well as serve as an ongoing strategic resource for all companies in the Flagship ecosystem supporting their clinical development strategies. Additionally, he will serve on the board of directors of several portfolio companies; he has served on the board of directors of the Flagship company Rubius Therapeutics since 2015.
EDIT: 25.75 (+0.03), TTOO: 6.98 (+1.32), AGIO: 45.22 (-0.01), MCRB: 10.01 (-0.93)

Agios Reports Favorable Phase II PK Deficiency Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 13, 8:56AM CDT
Agios Pharmaceuticals (AGIO) reported encouraging initial data from an ongoing phase II DRIVE-PK study on pyruvate kinase deficiency candidate AG-348.
PFE: 37.25 (+0.36), RTRX: 18.29 (+0.36), AGIO: 45.22 (-0.01), BMY: 75.64 (+0.83)

Agios Reports Initial Data from Phase 1 Study of AG-519 in Healthy Volunteers
GlobeNewswire - Thu Jun 09, 8:21AM CDT
- Data Demonstrate Favorable Safety Profile with up to 14 Days of Daily Dosing -
AGIO: 45.22 (-0.01)

What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma
PR Newswire - Thu Jun 02, 7:20AM CDT
Restructuring activities within the Biotech industry as well as the nearing U.S. presidential election continues to affect the overall condition of firms in this space. But despite the uncertainties, investors see potential growth in select companies that. Today, ActiveWallSt.com reviews the performances of the following equities: Genocea Biosciences Inc. (NASDAQ: GNCA), BioDelivery Sciences International Inc. (NASDAQ: BDSI), INSYS Therapeutics Inc. (NASDAQ: INSY), and Agios Pharmaceuticals Inc. (NASDAQ: AGIO). Click below to get your complimentary trade alerts:
BDSI: 2.39 (-0.16), INSY: 15.95 (+0.30), AGIO: 45.22 (-0.01), GNCA: 3.96 (-0.11)

Agios to Host Conference Call from the 21st Congress of the European Hematology Association
GlobeNewswire - Wed Jun 01, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Saturday, June 11, 2016 at 9:30 a.m. ET to discuss clinical and preclinical data presented at the 21st Congress of the European Hematology Association (EHA) taking place June 9-12, 2016 in Copenhagen.
AGIO: 45.22 (-0.01)

Agios to Present Clinical and Preclinical Data from PKR Activators AG-348 and AG-519 at the 21st Congress of the European Hematology Association
GlobeNewswire - Thu May 19, 6:01AM CDT
Initial Data to be Presented from AG-348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 45.22 (-0.01)

Agios Strikes Metabolic Immuno-Oncology Deal with Celgene
Zacks Equity Research - Zacks Investment Research - Wed May 18, 10:00AM CDT
Agios Pharmaceuticals (AGIO) inked a metabolic immuno-oncology agreement with Celgene; Agios gained global rights to AG-120 and updated 2016 view.
ANIP: 60.15 (-0.45), RTRX: 18.29 (+0.36), AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)

Agios and Celgene Establish New Collaboration in Metabolic Immuno-Oncology and Amend Certain Rights from 2010 Agreement
GlobeNewswire - Tue May 17, 3:01PM CDT
- New Collaboration Builds on Agios Research Platform and Leverages Celgene Capabilities; Agios to Receive $200 Million Upfront Payment -
AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02), CELGZ: 1.13 (-0.03)

Agios (AGIO) Q1 Loss Lower than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:51AM CDT
Agios Pharmaceuticals (AGIO) reported a first-quarter 2016 loss of 61 cents per share, much narrower than the Zacks Consensus Estimate of a loss of 69 cents.
ANIP: 60.15 (-0.45), RTRX: 18.29 (+0.36), AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)

Agios Pharmaceuticals reports 1Q loss
Automated Insights - Thu May 05, 2:45PM CDT
CAMBRIDGE, Mass. (AP) _ Agios Pharmaceuticals Inc. (AGIO) on Thursday reported a loss of $23.2 million in its first quarter.
AGIO: 45.22 (-0.01)

Agios Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 6:01AM CDT
Five Abstracts Accepted for Presentation at EHA in June, Including First Data from AG -348 Phase 2 DRIVE PK Study in PK Deficiency and AG-519 Phase 1 Healthy Volunteer Study
AGIO: 45.22 (-0.01)

Drug Stocks Earnings Preview: GERN, RPRX, ICPT, AGIO & More
Zacks Equity Research - Zacks Investment Research - Wed May 04, 10:25AM CDT
As we approach the end of this earnings season, investors will possibly heave a sigh of relief seeing that the going was not as bad as expected.
ABT: 45.14 (+0.39), BIIB: 304.77 (+14.84), CNAT: 2.30 (+0.04), AMGN: 173.90 (+1.87), RPRX: 1.95 (-0.17), JNJ: 125.50 (+0.27), GILD: 80.64 (+1.17), GWPH: 95.55 (+1.23), GERN: 2.70 (+0.02), AVEO: 0.98 (-0.02), ICPT: 172.48 (-0.55), AGIO: 45.22 (-0.01), NVS: 83.02 (-0.24)

What's in Store for Agios (AGIO) This Earnings Season?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:38PM CDT
Agios Pharmaceuticals (AGIO), which is set to report first-quarter 2016 results on May 5, delivered a negative surprise of 300% last quarter.
IPXL: 31.12 (-0.30), JAZZ: 150.37 (-0.60), AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)

Agios to Webcast Conference Call of First Quarter 2016 Financial Results on May 5, 2016
GlobeNewswire - Mon May 02, 7:30AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference call and live webcast on Thursday, May 5, 2016 at 8:30 a.m. ET to report its first quarter 2016 financial results and discuss recent clinical development and corporate activities.
AGIO: 45.22 (-0.01)

Mylan (MYL) Q1 Earnings: What's in the Cards for the Stock?
Zacks Equity Research - Zacks Investment Research - Thu Apr 28, 6:20AM CDT
Mylan (MYL), which is set to report first-quarter 2016 results on May 3, delivered a negative earnings surprise of 2.40% in the last quarter.
MYL: 46.52 (-0.27), AGIO: 45.22 (-0.01), GNCA: 3.96 (-0.11), SNY: 42.42 (-0.21)

Merrimack (MACK) Q1 Earnings: What's Ahead for the Stock?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 6:06PM CDT
Merrimack (MACK) will report first-quarter 2016 earnings on May 2 after the market closes.
ZTS: 50.50 (+0.03), MACK: 5.83 (+0.03), AGIO: 45.22 (-0.01), LLY: 83.19 (+0.30)

Prothena (PRTA): What's Ahead for the Stock in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Wed Apr 27, 5:42PM CDT
Prothena (PRTA) is expected to report first-quarter 2016 earnings on May 3.
ZTS: 50.50 (+0.03), AGIO: 45.22 (-0.01), PRTA: 55.69 (+0.64)

Agios Announces Initiation of Phase 1/2 Frontline Combination Study of AG-221 or AG-120 with VIDAZA(R) (azacitidine for injection) in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Not Eligible for Intensive Chemotherapy
GlobeNewswire - Wed Mar 30, 6:01AM CDT
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced the initiation of a Phase 1/2, multicenter, international, open-label study, sponsored by Celgene Corporation, of AG-221 or AG-120 in combination with VIDAZA (azacitidine for injection) in patients with newly diagnosed acute myeloid leukemia (AML) with an isocitrate dehydrogenase (IDH) mutation who are not eligible for intensive chemotherapy. AG-221 and AG-120 are first-in-class, oral, selective, potent inhibitors of mutant IDH2 and IDH1, respectively, and are being developed in collaboration with Celgene.
AGIO: 45.22 (-0.01)

The Silly Reason Why Agios Pharmaceuticals Inc. Was Clobbered in January
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 06, 6:32AM CST
What: Shares of Agios Pharmaceuticals , a clinical-stage drug developer primarily focused on researching cancer and rare-disease treatments, were hammered in January, falling 35% based on data from S&P Capital IQ . The primary culprit behind...
AGIO: 45.22 (-0.01), CELG: 114.21 (+2.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ballard's Q3 2026: Navigating Losses and Bold Moves

Updated Category News Views 29

Ballard’s Financial Puzzles in Q3 2026 Riding the rough waters of the third quarter in 2026, Ballard Power Systems set out its stall with some eyebrow-raising numbers. This ain't the bustling diner vibe we normally see for a thriving business. The results paint a cautious picture sprinkled with strategic shifts that demand a keen eye. GeoPura Acquisition: A Strategic...

Continue Reading
Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 97

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 181

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 74

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
WirelessCar Rebrands to Reinforce Connected Mobility Vision

Updated Category News Views 41

Evolving Identity for Changing Times Let’s dive right into it—WirelessCar, a name that’s struck chords in the automotive trenches for ages, is taking a bold step by unveiling a new brand identity. Now, don’t roll your eyes just yet. This isn’t another company tapping the rebranding siren for the heck of it. We’re talking about a company that’s been in the...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 112

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 67

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 635

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
AI Pushes Asset Managers Towards New Investment Growth

Updated Category News Views 5

AI: A Double-Edged Sword for Asset Managers Peeled straight from the heart of New York's financial buzz, AI is changing the game for asset and wealth managers. Now, we ain’t talking about some futuristic sci-fi scene, but real-world shifts that are scratching their way into boardrooms. Nearly 80% of firms playing the AI card see a sweet lift in productivity and...

Continue Reading

Top 5 Most Recently Viewed Articles

Movable Ink Boosts AI Marketing Strategies with Global Expansion

Updated Category News Views 165

Movable Ink Expands its AI Marketing Solutions Across Europe Movable Ink, a leader in AI-powered personalisation, has significantly boosted its presence in Europe. The company’s innovative approach, termed the Autonomous Marketing strategy, is proving to reshape the marketing landscape. Now, with the launch of its sophisticated Da Vinci product, Movable Ink is setting a...

Continue Reading
Crypto Market Update: Election Impact on Bitcoin and Ethereum

Updated Category News Views 110

Market Movements Amid Election Uncertainty In recent days, leading cryptocurrencies have experienced a noticeable pullback. The shifts in market sentiment appear closely linked to the political atmosphere, particularly surrounding presidential election predictions. As the likelihood of Donald Trump's election victory declined, key cryptocurrencies like Bitcoin and...

Continue Reading
Festi hf. Receives Non-Binding Offers for Olíudreifing ehf.

Updated Category News Views 101

Festi hf. Receives Non-Binding Offers for Olíudreifing ehf. Festi hf. has recently announced the progress concerning Olíudreifing ehf. which is a crucial infrastructure entity specializing in fuel storage and distribution in Iceland. After initiating the sales process on September 26, 2024, the company has now received non-binding offers for all outstanding shares in...

Continue Reading
Canadian Solar Plans US$200 Million Convertible Notes Offering

Updated Category News Views 141

Canadian Solar Announces Offering of Convertible Senior Notes Canadian Solar Inc. (NASDAQ: CSIQ) has recently disclosed plans for the proposed offering of US$200 million in convertible senior notes due 2031. This offering is contingent upon market conditions and other factors. The convertible notes are set to be offered and sold privately to qualified institutional...

Continue Reading
HPQ Silicon Achieves Milestone with First Battery Cell Shipments

Updated Category News Views 185

HPQ Silicon's Exciting Development in Battery Technology HPQ Silicon Inc. (“HPQ”) is thrilled to announce that it has successfully completed and shipped its first industrial batches of high-performance lithium-ion battery cells. Manufactured using their innovative GEN3 silicon-based anode material, these initial cells, which come in the 18650 and 21700 formats under...

Continue Reading